Last reviewed · How we verify
IDCT (rebonuputemcel)
IDCT (rebonuputemcel) is an allogeneic juvenile chondrocyte cell therapy designed to regenerate cartilage and restore joint function in degenerative disc disease.
IDCT (rebonuputemcel) is an allogeneic juvenile chondrocyte cell therapy designed to regenerate cartilage and restore joint function in degenerative disc disease. Used for Degenerative disc disease of the lumbar spine.
At a glance
| Generic name | IDCT (rebonuputemcel) |
|---|---|
| Sponsor | DiscGenics, Inc. |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Spine |
| Phase | Phase 3 |
Mechanism of action
Rebonuputemcel consists of allogeneic (donor-derived) juvenile chondrocytes that are administered directly into the intervertebral disc to promote cartilage regeneration and restore disc height and function. The cells are intended to replace damaged or degenerated disc tissue and slow or reverse the progression of degenerative disc disease by restoring the structural and functional integrity of the nucleus pulposus.
Approved indications
- Degenerative disc disease of the lumbar spine
Common side effects
- Back pain
- Injection site reactions
- Leg pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDCT (rebonuputemcel) CI brief — competitive landscape report
- IDCT (rebonuputemcel) updates RSS · CI watch RSS
- DiscGenics, Inc. portfolio CI